Although there have been several reports on the development of anti-CEA reagents from recombinant antibody technology26,27, based on the promising potential of Affimers as alternative affinity reagents, we postulated that generation of CEA binding Affimers could facilitate the acceleration of diagnostics and treatment of CRC and other cancers. The gene discussed is CEACAM5; the disease is colorectal carcinoma.